Imricor Medical Systems (ASX:IMR) submitted its second premarket approval module for US Food and Drug Administration (FDA) review, according to a Tuesday filing with the Australian bourse.
The module covers design, manufacturing, and quality processes for seven products, and includes design controls, raw material receipt, inspection, storage, build procedures, process validation, part and device traceability, and quality management systems, the filing said.
The company's NorthStar 3D mapping and guidance system will be submitted next under the 510(k) process.
Shares fell nearly 3% in morning trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.